“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like Pfizer Strikes Deal With Array BioPharma on Anti-Cancer Development December 18, 2017 5 Big Pharmas Facing Catalysts in 2017 May 25, 2017 Martin Shkreli Ordered to Forfeit $7.36 Million in Assets Ahead of Sentencing March 5, 2018
